Search
Zilganersen
go.drugbank.com/drugs/DB18161ApprovedInvestigational[L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition
Ansuvimab
go.drugbank.com/drugs/DB16385Approved[A207646] Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD.
AMZ002
go.drugbank.com/drugs/DB17017InvestigationalAMZ002 is a sterile injectable hormone developed as a purified synthetic polypeptide alternative to current FDA-approved epileptic seizure treatments.
Ensulizole
go.drugbank.com/drugs/DB11115ApprovedAccording to the FDA, the maximal approved concentration of ensulizole is 148 mM although concentrations ranging between 74 and 148mM can be found in commercial sunscreen products [A27151].
Olipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145]
Lasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnIt was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal atrophy, in which were both rejected for approval by FDA.
Risdiplam
go.drugbank.com/drugs/DB15305ApprovedInvestigational[L15351,A216871] Risdiplam was approved by the FDA in August 2020 for the treatment of spinal muscular atrophy (SMA).
Metoclopramide
go.drugbank.com/drugs/DB01233ApprovedInvestigational[T683] Metoclopramide was initially approved by the FDA in 1980.[A184922]
Glycyrrhizic acid
go.drugbank.com/drugs/DB13751ApprovedInvestigational[A33062] From January 2014, glycyrrhizic acid as part of the licorice extract was approved by the FDA as an existing food sweetener.
Nalmefene
go.drugbank.com/drugs/DB06230ApprovedInvestigationalWithdrawn[L40684] The nasal spray formulation of nalmefene was approved by the FDA in May 2023.[L46511]